The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01A | Alkylating agents | |
| 4 | L01AX | Other alkylating agents |
| Code | Title | |
|---|---|---|
| L01AX01 | Mitobronitol | |
| L01AX02 | Pipobroman | |
| L01AX03 | Temozolomide | |
| L01AX04 | Dacarbazine |
| Active Ingredient | Description | |
|---|---|---|
| Dacarbazine |
Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. |
|
| Temozolomide |
Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC). The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position. Cytotoxic lesions that develop subsequently are thought to involve aberrant repair of the methyl adduct. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DACARBAZINE Powder for solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TEMODAL Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| TEMODAL Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
